Title
Tubular β-catenin and FoxO3 interactions protect in chronic kidney disease
Date Issued
01 May 2020
Access level
open access
Resource Type
journal article
Author(s)
Nlandu-Khodo S.
Osaki Y.
Scarfe L.
Yang H.
Phillips-Mignemi M.
Tonello J.
Neelisetty S.
Ivanova A.
Huffstater T.
McMahon R.
Taketo M.M.
De Caestecker M.
Kasinath B.
Harris R.C.
Lee E.
Gewin L.S.
Universidad de Vanderbilt
Publisher(s)
American Society for Clinical Investigation
Abstract
The Wnt/β-catenin signaling pathway plays an important role in renal development and is reexpressed in the injured kidney and other organs. β-Catenin signaling is protective in acute kidney injury (AKI) through actions on the proximal tubule, but the current dogma is that Wnt/β-catenin signaling promotes fibrosis and development of chronic kidney disease (CKD). As the role of proximal tubular β-catenin signaling in CKD remains unclear, we genetically stabilized (i.e., activated) β-catenin specifically in murine proximal tubules. Mice with increased tubular β-catenin signaling were protected in 2 murine models of AKI to CKD progression. Oxidative stress, a common feature of CKD, reduced the conventional T cell factor/lymphoid enhancer factor-dependent β-catenin signaling and augmented FoxO3-dependent activity in proximal tubule cells in vitro and in vivo. The protective effect of proximal tubular β-catenin in renal injury required the presence of FoxO3 in vivo. Furthermore, we identified cystathionine γ-lyase as a potentially novel transcriptional target of β-catenin/FoxO3 interactions in the proximal tubule. Thus, our studies overturned the conventional dogma about β-catenin signaling and CKD by showing a protective effect of proximal tubule β-catenin in CKD and identified a potentially new transcriptional target of β-catenin/FoxO3 signaling that has therapeutic potential for CKD.
Volume
5
Issue
10
Language
English
OCDE Knowledge area
Urología, Nefrología
Scopus EID
2-s2.0-85085264535
PubMed ID
Source
JCI Insight
ISSN of the container
2379-3708
Sponsor(s)
This work was supported by NIH grants R01-DK-108968-01 (LG), DK51265 (RCH), R35GM122516 (EL), 1R01DK112688 (MD), and W81XWH-17-1-0610 (MD); Vanderbilt O’Brien Kidney Center NIH grant 1-P30-DK-114809-01 (LG); Swiss National Science Foundation; Ambizione grant PZ00P3_179916 (SNK); and the Vanderbilt Center for Kidney Disease, Department of Veterans Affairs, Veterans Health Administration VA Merit Awards 1I01BX003425-01A1 (LG), 00507969 (RCH), and I01BX001340 (BK).
Sources of information: Directorio de Producción Científica Scopus